Answer
Rifampicin, a potent CYP inducer, decreases tofacitinib citrate exposure (AUC and peak concentration), potentially reducing or eliminating clinical response, and coadministration is not recommended.
Sources for this answer
- XELJANZ 5mg film-coated tabletsPfizer Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 33Document updated
Sources checked